IVMED-95

**IVMED-95** is a preclinical-stage ophthalmic therapeutic agent developed by iVeena Delivery Systems, Inc. for treating adult low myopia, a condition characterized by nearsightedness due to excessive axial elongation of the eye. It works by flattening the cornea through pharmacologic mechanisms that promote corneal remodeling, potentially leveraging extracellular matrix stabilization similar to related iVeena programs. No specific mechanism of action, active ingredient, or clinical data have been publicly disclosed, distinguishing it from iVeena's IVMED-80 (copper sulfate eye drops activating lysyl oxidase for keratoconus).[1][3][7][11][12]